anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study aimed to establish the diagnostic criteria for upper gastrointestinal bleeding (UGIB) using postmortem computed tomography (PMCT). This case-control study enrolled 27 consecutive patients with autopsy-proven UGIB and 170 of the 566 patients without UGIB who died in a university hospital in Japan after treatment and underwent both noncontrast PMCT and conventional autopsy between 2009 and 2020. Patients were randomly allocated to two groups: derivation and validation sets. Imaging findings of the upper gastrointestinal contents, including CT values, were recorded and evaluated for their power to diagnose UGIB in the derivation set and validated in the validation set. In the derivation set, the mean CT value of the upper gastrointestinal contents was 48.2 Hounsfield units (HU) and 22.8 HU in cases with and without UGIB. The optimal cutoff CT value for diagnosing UGIB was ≥27.7 HU derived from the receiver operating characteristic curve analysis (sensitivity, 91.7%; specificity, 81.2%; area under the curve, 0.898). In the validation set, the sensitivity and specificity in diagnosing UGIB for the CT cutoff value of ≥27.7 HU were 84.6% and 77.6%, respectively. In addition to the CT value of ≥27.7 HU, PMCT findings of solid-natured gastrointestinal content and intra/peri-content bubbles ≥4 mm, extracted from the derivation set, increased the specificity for UGIB (96.5% and 98.8%, respectively) but decreased the sensitivity (61.5% and 38.5%, respectively) in the validation set. In diagnosing UGIB on noncontrast PMCT, the cutoff CT value of ≥27.7 HU and solid gastrointestinal content were valid and reproducible diagnostic criteria.
Monomorphic PTLD comprise more than 70% of PTLDs and diffuse large B-cell lymphoma is the predominant subtype. However, none of the trials have been performed for the specific population of DLBCL type monomorphic PTLD. The investigators will select Patients with proven, measurable monomorphic PTLD of DLBCL after solid organ transplantation (e.g. heart, lung, liver or kidney etc.). Patients having PTLD with or without Epstein-Barr virus (EBV) association, positive for CD20 monomorphic DLBCL type. The B-R treatment will continue up to 6 cycles with interval of 21 days. Patients will receive 375 mg/m2 on day 1 and bendamustine 120 mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400 mg and bendamustine 120 mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2. On the first day of infusion of bendamustine in each cycle, palonosetron 0.25 mg will be given as a single intravenous injection about 30 minutes before infusion of bendamustine. Pegfilgrastim 6 mg will be administered as a single subcutaneous injection between 24 to 48 hours after completion of chemotherapy at each cycle. Based on relatively good safety profile and efficacy of bendamustine and rituximab (BR regimen), the investigators will investigate a feasibility of BR regimen in this immunocompromised patients with DLBCL type monomorphic PTLD.
Therapeutic compositions for application to the skin in the treatment of acne comprise a suspension of an inorganic abrasive having a harness greater than 7, as measured by Moh's index, being non-piezo-electric and having a particle size distribution within the range of 125 microns to 710 microns, in a non-oleaginous paste comprising a surface active agent and a solvent therefor, which is non-poisonous and non-irritating to the skin.  The preferred abrasive is fused, synthetic aluminium oxide and the surface active agent may be cationic, anionic or non-ionic.  The solvent is preferably water but may also be an organic liquid.  An emollient may be included in the non-oleaginous paste, e.g. lanolin, glycerine, polyethylene glycol or a fatty acid ester of polyethylene glycol.  Other optional ingredients which may be included are pigments, bentonite, and bactericides, e.g. hexachlorophene, 3, 4, 41-trichlorocarbanilide and bithionol.  In a course of treatment for acne, a coordinated series of compositions according to the invention may be used, in which the proportion of coarse to fine particles of the abrasive and the proportion of abrasive to non-oleaginous paste are both successively increased in successive stages of the treatment.
The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention has effects of inhibiting the proliferation of cancer cells, decreasing the mobility of cancer cells, inhibiting the neoangiogenesis, and increasing the anticancer immune response as well as reducing the expression of inflammatory factors, thereby having effects of preventing or treating cancers or inflammatory diseases. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. In addition, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits effects of directly inhibiting the proliferation of cancer cells and enhancing immunity, thereby having effects of preventing or treating cancers. In particular, the strain has an excellent anticancer effect by secreting metabolites having an anticancer effect while being established in the gut. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Lactococcus lactis GEN3033 strain of the present invention exhibits a better anticancer effect.
The invention belongs to the medical technical field and discloses a drug combination for the cardiovascular disease and the preparation method of the drug combination. The drug combination contains the pharmacodynamic components of the raw materials of drugs of danshen root, Szechwan lovage rhizome, panax notoginseng, milkvetch root and storax. In order to achieve a better curative effect, a leech, tonka beans and peach nuts can also be added into the drug combination; in order to further improve the curative effect, rosewood, axillary choerospondias fruit and earthworms can be added into the drug combination. The drug combination of the invention has the efficacies of promoting the circulation of qi to induce resuscitation, activating blood circulation for removing blood stasis, dredging channels for alleviating pain etc. and is used for preparing the drugs for remedying the cerebral infarction convalescence of the coronary heart disease, the angina pectoris or the arteriosclerosis, the syndrome of which belong to the qi stagnation and blood stasis with the symptoms of chest pain, oppression in the chest, shortness of breath, heart throb, inefficaciousness of limbs, inarticulacy etc. The drug combination of the invention can be made into any preparation type, which is acceptable in the clinic and the pharmacy, and the oral preparation is preferential.
The recommended dosage of mitoxantrone is 12 mg/m2 given as a short (approximately 5 to 15 minutes) intravenous infusion every 3 months. Left ventricular ejection fraction (LVEF) should be evaluated by echocardiogram or MUGA prior to administration of the initial dose of mitoxantrone and all subsequent doses. In addition, LVEF evaluations are recommended if signs or symptoms of congestive heart failure develop at any time during treatment with mitoxantrone. Mitoxantrone should not be administered to multiple sclerosis patients with an LVEF <50%, with a clinically significant reduction in LVEF, or to those who have received a cumulative lifetime dose of ≥140 mg/m2. Complete blood counts, including platelets, should be monitored prior to each course of mitoxantrone and in the event that signs or symptoms of infection develop. Mitoxantrone generally should not be administered to multiple sclerosis patients with neutrophil counts less than 1500 cells/mm3. Liver function tests should also be monitored prior to each course. Mitoxantrone therapy in multiple sclerosis patients with abnormal liver function tests is not recommended because mitoxantrone clearance is reduced by hepatic impairment and no laboratory measurement can predict drug clearance and dose adjustments.

Women with multiple sclerosis who are biologically capable of becoming pregnant, even if they are using birth control, should have a pregnancy test, and the results should be known, before receiving each dose of mitoxantrone (see WARNINGS, Pregnancy).
The use of multiple anticonvulsants may result in an increase of CNS depressant adverse effects. This should be considered before adding Klonopin to an existing anticonvulsant regimen.

### Adults

The initial dose for adults with seizure disorders should not exceed 1.5 mg/day divided into three doses. Dosage may be increased in increments of 0.5 to 1 mg every 3 days until seizures are adequately controlled or until side effects preclude any further increase. Maintenance dosage must be individualized for each patient depending upon response. Maximum recommended daily dose is 20 mg.

### Pediatric Patients

Klonopin is administered orally. In order to minimize drowsiness, the initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day but not to exceed 0.05 mg/kg/day given in two or three divided doses. Dosage should be increased by no more than 0.25 to 0.5 mg every third day until a daily maintenance dose of 0.1 to 0.2 mg/kg of body weight has been reached, unless seizures are controlled or side effects preclude further increase. Whenever possible, the daily dose should be divided into three equal doses. If doses are not equally divided, the largest dose should be given before retiring.

### Geriatric Patients

There is no clinical trial experience with Klonopin in seizure disorder patients 65 years of age and older. In general, elderly patients should be started on low doses of Klonopin and observed closely (see PRECAUTIONS: Geriatric Use).
DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
A device for treating at least one infected nail of at least one digit of a subject includes an enclosure sized for housing at least a distal end of at least one digit of a subject having at least one infected nail. The enclosure comprises an integrally molded elastomeric polymer sheath having an interior cavity, which substantially conforms to the size and shape of at least the distal end of the at least one digit of the subject having the at least one infected nail. The sheath has an open end and a closed end, tapering from the closed end to the open end. The elastomeric polymer sheath comprises an elastomeric polymer film having oil resistance and low oxygen permeability. A method of using the device to treat the infected nail is provided. A kit including the device and an antifungal treatment composition is disclosed for treating the infected nail.
Treatment corresponding to standard practice : interruption of Imatinib from the day of randomization. Reintroduction of Imatinib at 400 mg/day after first relapse according to RECIST 1.1 criteria; Then increase dose to 800 mg/day after 2d relapse. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib SPC.
Volunteers will receive and intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase 1, MNLBR 110) in the volar aspect of the arm. Skin test will be evaluated; if erythema occurs after the skin test, it is medically contraindicated to vaccinate that volunteer. Volunteers with skin test reactions will not be vaccinated and withdrawn from the study.
The present invention provides an amphiphilic linear peptide and/or peptoid as well as a hy-drogel that includes the amphiphilic linear peptide/peptoid. The amphiphilic linear pep-tide/peptoid is capable of forming a hydrogel. These peptides/peptoids include short amphi-philic sequences with a hydrophobic portion of aliphatic amino acids and at least one acidic, neutral, or basic polar amino acid. The amphiphilic linear peptide/peptoid is build up of non repetitive aliphatic amino acids, which may be in the L- or D-form. A plurality of such pep-tides/peptoids assembles to supramolecular helical fibers and forms peptide hydrogels after assembly. A corresponding hydrogel is formed in aqueous solutions at physiological pH and is thus useful for inter alia cell culture, tissue engineering, and drug release. Such hydrogels which are rigid, biocompatible and entrapping up to 99.9% of water are also well suited for applications utilizing electronic devices.
Provided are a computer program product, system, and method for providing supplemental information for a patient report to produce an updated patient report processed to determine medical findings and a medical best practice recommendation. A patient report is processed to determine supplemental information and transmit to the user interface to render. A first updated patient report is received including content for the supplemental information. A classifier program processes the first updated patient report including the content for the supplemental information to classify into a medical finding. A determination is made of a medical best practice recommendation associated with the medical finding. The medical finding and the medical best practice recommendation are transmitted to the user interface to render. A second updated patient report is received including at least one of the medical finding and the medical best practice recommendation the user selected to include.
The guanidines and ethylenediamine derivatives disclosed herein are selective …<SB>3</SB> adrenergic receptor agonists with very little …<SB>1</SB> and …<SB>2</SB> adrenergic receptor activity. Further, such compounds are capable of increasing lipolysis and energy expenditure in cells. The said compounds thus have potent activity in the treatment of Type II diabetes and obesity. The said compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the said compounds can be used to reduced neurogenic inflammation or as antidepressant agents. Compositions and methods for the use of the said compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.
Alterations in the cellular redox state play a critical role in cell signaling and cell activation, suggesting that administration of sulflhydryl-reactive agents have important modulatory effects on the inflammatory response. Intracellular thiol depletion attenuates the pulmonary inflammatory response following intratracheal administration of endotoxin (LPS), and this attenuation supersedes the reduction in antioxidant defenses associated with depletion of the endogenous antioxidant, glutathione (GSH). Sprague Dawley rats were administered diethylmaleate (DEM, 6 mmole/kg), a rapidly acting GSH-depleting agent, followed by intratracheal administration of LPS. Lung injury was assessed by measuring the transpulmonary flux of 125l albumin and expressed as a permeability index (Pl). Administration of DEM reduced lung GSH levels from 1310~114 to 185~48 nmoles/g. This was associated with a reduction in the Pl following LPS treatment (LPS: 0.22~0.03 vs LPS+DEM: 0.03~0.01). Bronchoalveolar lavage fluid PMN counts were markedly reduced in animals pretreated with DEM (LPS: 90.5~24x106 vs LPS+DEM: 1 .9~0.4x106). The reduction in lung neutrophil sequestration was not due to an effect on the neutrophil, as peripheral blood PMN isolated from DEM-treated animals had equivalent chemotactic responses to fMLP, and normal upregulation of CD11b. DEM pretreatment mitigated LPS induced upregulation of lung lCAM-1 protein and mRNA expression as demonstrated by immunohistochemistry and Northern analysis, respectively. DEM attenuates LPS-induced lung injury by preventing lung PMN sequestration. This effect appears to be mediated through abrogation of endothelial lCAM-1 upregulation in response to LPS. These data suggest that intracellular thiols modulate lCAM-1 expression.
Serious rash requiring hospitalization and discontinuation of treatment has been reported in association with the use of armodafinil or modafinil (the racemic mixture of S- and R-enantiomers).

Armodafinil has not been studied in pediatric patients in any setting and is not approved for use in pediatric patients for any indication.

In clinical trials of modafinil, the incidence of rash resulting in discontinuation was approximately 0.8% (13 per 1,585) in pediatric patients (age <17 years); these rashes included 1 case of possible Stevens-Johnson syndrome (SJS) and 1 case of apparent multi-organ hypersensitivity reaction/Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) [see Warnings and Precautions (5.2)]. Several of the cases were associated with fever and other abnormalities (e.g., vomiting, leukopenia). The median time to rash that resulted in discontinuation was 13 days. No such cases were observed among 380 pediatric patients who received placebo.

Skin and mouth sores, blistering, and ulceration have been reported with modafinil and armodafinil in the postmarketing setting. Recurrence of signs and symptoms of serious dermatologic reactions following rechallenge has been reported in some cases.

Rare cases of serious or life-threatening rash, including SJS and toxic epidermal necrolysis (TEN), have been reported in adults and children in worldwide postmarketing experience with modafinil and armodafinil.

There are no factors, including duration of therapy, that are known to predict the risk of occurrence or the severity of rash associated with modafinil or armodafinil. In cases where the time to onset was reported, serious rash occurred 1 day to 2 months after initiation of treatment, but isolated cases of serious dermatologic reactions have been reported with symptoms beginning after prolonged treatment (e.g., 3 months).

Although benign rashes also occur with armodafinil, it is not possible to reliably predict which rashes will prove to be serious. Accordingly, armodafinil should be discontinued at the first sign of rash, skin or mouth sores, or blistering or ulceration, unless the rash is clearly not drug-related. Discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.
Current asthma guidelines recommend stepping down therapy once asthma is controlled for at least 3 months. For patients treated with inhaled corticosteroids (ICS) alone, a dose reduction of 25-50% to a minimal dose that controls disease is recommended. The optimal approach to reducing treatment in patients with asthma treated with combination inhaled corticosteroids and long-acting beta agonists (ICS/LABA) is not clear. The American Lung Association Asthma Clinical Research Center (ALAACRC) is a network of 18 asthma research centers with the goal of performing clinical trials directly relevant to clinical practice. The question of the optimal way to de-escalate therapy in patients with asthma that is well controlled on fixed dose combination ICS/LABA is a key question for practitioners caring for patients with moderate to severe persistent asthma. We propose a 56 week multi-center, prospective, randomized, three-arm parallel group comparative effectiveness study comparing three approaches to care of patients with asthma well-controlled for three months on combination ICS/LABA: reduction of ICS dose and maintenance of LABA, initial discontinuation of LABA with continuation of ICS, and continuation of stable dose ICS/LABA. Our primary goal is to perform a pragmatic study that resembles clinical practice and determine the optimal treatment strategy that results in the lowest rate of treatment failure over 48 weeks of follow-up. Additional exploratory analyses include assessing risk factors for step-down failure, and to assess the duration of time that asthma control is maintained when therapy is de-escalated.
The invention provides an improved Chinese medicine combination for treating heart diseases. The improved Chinese medicine combination is a powdery drug and is mainly prepared by mixing 0.5-2.5 parts of large leaf toss, 0.3-1.5 parts of ginseng and 0.3-1.5 parts of salvia miltiorrhiza. Angelica and borneol or/and clinopodium herb can also be added on the basis. The drug is mainly prepared into the forms of capsules and tablets and can also be made into directly taken large honey pills with honey and brown sugar. The improved Chinese medicine combination has remarkable therapeutic effects on myocardial infarction, myocarditis, angina, rheumatic heart disease, coronary heart disease, sudden heart disease, mental asthenia, arrhythmia, myocardial ischemia, psychoneurosis, heart palpitation, septic shock, palpitation blindness and the like. The improved Chinese medicine combination does not have toxic or side effects, and the long-term administration of the improved Chinese medicine combination is safe and reliable.